Management of aseptic meningitis secondary to intravenous immunoglobulin

doi:10.1136/bmj.316.7135.936

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Stephen Jolles, Senior registrar (stephenj@westmed.wh.su.edu.au),
Helen Hill, Nurse consultant in immunology

Department of Clinical Immunology, Westmead 2145, Sydney, Australia

EDITOR—Picton and Chisholm describe a case of aseptic meningitis related to high dose intravenous immunoglobulin diagnosed on the basis of eosinophils in the cerebrospinal fluid.1 This adverse effect varies in presentation from a transient headache after the infusion to vomiting, photophobia, neck stiffness, and severe headache. The timing of symptoms may be delayed by up to seven days, though most occur within 48 hours after the treatment.2 The symptoms are …